TITLE

Non--Organ-Specific Autoantibodies in Children with Chronic Hepatitis C: Clinical Significance and Impact on Interferon Treatment

AUTHOR(S)
Muratori, Paolo; Muratori, Luigi; Verucchi, Gabriella; Attard, Luciano; Bianchi, Francesco B.; Lenzi, Marco
PUB. DATE
November 2003
SOURCE
Clinical Infectious Diseases;11/15/2003, Vol. 37 Issue 10, p1320
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We evaluated the prevalence and clinical significance of non­organ-specific autoantibodies (NOSAs) in 47 hepatitis C virus (HCV)­positive children with abnormal alanine transaminase levels and analyzed the association between NOSAs and virus level, genotype, human leukocyte antigen status, and interferon (IFN) response. Forty-two hepatitis B virus (HBV)­positive children and 25 age- and sex-matched healthy children served as control subjects. NOSAs were found in 34% of the HCV­positive children, 12% of the HBV­positive controls, and none of the healthy control subjects. Liver-kidney microsomal antibody type 1 (LKM1) was detected in 11% of the HCV­positive children but in none of the controls. The HCV load was significantly higher in NOSA-negative than in NOSA-positive children. HCV genotype distribution and human leukocyte antigen alleles were similar, irrespective of NOSA status. Long-term response to IFN therapy was achieved by 18% of the NOSA-positive and 55% of the NOSA-negative subjects. Two LKM1-positive children developed acute, self-limited hepatocellular necrosis while receiving IFN therapy. NOSAs are frequently present in children with hepatitis C, who are less likely to benefit from IFN therapy.
ACCESSION #
11471017

 

Related Articles

  • Skin Reaction in Antiviral Therapy for Chronic Hepatitis C: A Role for Polyethylene Glycol Interferon? Cottoni, Francesca; Bolognini, Silvia; Deplano, Angelo; Garrucciu, Giovanni; Manzoni, Noemi Elisabetta; Careddu, Giovanna Francesca; Montesu, Maria Antonia; Tocco, Andreina; Lissia, Amelia; Solinas, Antonio // Acta Dermato-Venereologica;Mar2004, Vol. 84 Issue 2, p120 

    In the past decade, different modalities of antiviral therapy have been adopted aimed at eradicating hepatitis C virus infection. Initially, interferon was used in monotherapy, then interferon combined with ribavirin and amantadine. Recently, interferon has been conjugated with polyethylene...

  • NON-HEMATOLOGIC ADVERSE EFFECTS RELATED TO INTERFERON HERAPY IN PATIENTS WITH CHRONIC HCV HEPATITIS. Cristina, Popescu; Victoria, Aramă // Therapeutics, Pharmacology & Clinical Toxicology;Jun2012, Vol. 16 Issue 2, p77 

    Pegylated interferon and ribavirin are mandatory in the treatment of HCV hepatitis. An early recognition of side effects related to the antiviral therapy can prevent the discontinuation of treatment and can improve the eradication of HCV infection. Hematologic side effects related to pegylated...

  • INTRAVENOUS INTERFERON-BETA IN CHRONIC HEPATITIS B: PROMISES. Koff, Raymond S. // American Journal of Gastroenterology;Feb1993, Vol. 88 Issue 2, p171 

    Explores the use of intravenous interferon-beta for the treatment of adult patients with compensated chronic hepatitis B in the U.S. Limitations of the antiviral treatment of chronic hepatitis B; Factors which affect the long-term effectiveness of anti-hepatitis B virus therapy; Examination of...

  • Hepatitis G Virus Infection in Hemodialysis Patients and the Effects of Interferon Treatment. Umlauft, Florian; Wong, David T.; Underhill, Peter A.; Oefner, Peter J.; Li Jin; Urbanek, Martina; Gruenewald, Kurt; Greenberg, Harry B. // American Journal of Gastroenterology;Nov1997, Vol. 92 Issue 11, p1986 

    Objective: To characterize the nature of hepatitis G virus (HGY) infections in hemodialysis patients and to determine the responsiveness of HGV to antiviral therapy in these patients. Methods: HGV, a recently identified flavivirus, is associated with non-A-E viral hepatitis infections. We...

  • Efficacy of Short-Term Interferon Therapy for Patients Infected with Hepatitis C Virus Genotype 2a. Tabaru, Akinari; Narita, Ryoichi; Hiura, Masaaki; Abe, Shintaro; Otsuki, Makoto // American Journal of Gastroenterology;Apr2005, Vol. 100 Issue 4, p862 

    BACKGROUND AND AIMS: The efficacy of interferon (IFN)-based antiviral therapy for chronic hepatitis C (CHC) varies depending on predictive factors such as hepatitis C virus (HCV) genotype and viral load. For patients with good predictive factors, a low dose and short course of IFN-based therapy...

  • PCBP2 Enhances the Antiviral Activity of IFN-α against HCV by Stabilizing the mRNA of STAT1 and STAT2. Xin, Zhongshuai; Han, Wei; Zhao, Zhiqiang; Xia, Qing; Yin, Bin; Yuan, Jiangang; Peng, Xiaozhong // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Interferon-α (IFN-α) is a natural choice for the treatment of hepatitis C, but half of the chronically infected individuals do not achieve sustained clearance of hepatitis C virus (HCV) during treatment with IFN-α alone. The virus can impair IFN-α signaling and cellular factors that...

  • Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT. Jacobson, Ira M.; Ahmed, Furqaan; Russo, Mark W; Lebovics, Edward; Dieterich, Douglas T.; Esposito, Stephen P.; Bach, Nancy; Klion, Franklin; Tobias, Hillel; Antignano, Louis; Brown Jr., Robert S.; Gabbaizadeh, David; Geders, Jane; Levendoglu, Hulya // American Journal of Gastroenterology;Sep2004, Vol. 99 Issue 9, p1700 

    OBJECTIVES: Most studies establishing the role of antiviral therapy in patients with chronic hepatitis C (CHC) excluded the patients with normal ALT levels. Small trials with interferon monotherapy suggested a limited efficacy and/orde novoALT elevations. We sought to evaluate the efficacy of...

  • Research on interferon: a review. Tyrrell, D. A. J. // Journal of the Royal Society of Medicine;Feb1981, Vol. 74 Issue 2, p145 

    The article offers information about interferon. According to the research, interferon was discovered in 1957 after years of studying the virus interference. After its discovery, it was then initially suggested that interferon might be used as an antiviral drug. However, it was soon revealed...

  • Interferon beta may help to treat asthma. Bowden, Rachel // GP: General Practitioner;7/1/2005, p3 

    This article informs that according to a British research, interferon beta may help prevent or treat exacerbations of asthma that are caused by infection with a common cold virus. The researchers studied the immune response to infection with a rhinovirus in cultures of bronchial epithelial cells...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics